A methodology for calculating the rarity of diverse proteins based on functional specificity and thermodynamic stability Authors: Brian J. Miller Published: 2025 ABSTRACT A key question in protein studies is the proportion of amino acid sequences that correspond to functional proteins, often called protein rarity. This issue underlies the relationship between mutations and disease, theories on the origin of proteins, and strategies for engineering new proteins. Recent literature has detailed how to employ estimates of protein rarity to evaluate the required biasing of functional sequences in sequence space to allow for evolutionary paths to connect distinct proteins. One challenge in addressing rarity has been an imprecise definition of function and a lack of consistency in methodology. This study introduces a new methodology, referred to as PRISM, to evaluate protein rarity based on the impact of mutations on stability. PRISM offers a suite of methods that are simpler than traditional approaches while providing accurate upper-bound rarity estimates. The specific method applied is determined by the protein’s function and available empirical data on how accumulating mutations affect its stability and performance. PRISM is applied to several proteins, and the accuracy of the methods is demonstrated by comparing the results to rarity estimates from previous studies. The calculated rarities align with previous research that concludes functional sequences are often exceedingly rare. The application of PRISM is outlined for research in protein engineering, protein evolution, and pathology. Introduction Protein rarity studies A fundamental question in protein studies is the rarity of amino acid (aa) sequences in sequence space (aka “protein rarity”) that generate functional protein folds. Sequence space is the high-dimensional space of all possible amino acid sequences or nucleotide sequences in the corresponding open reading frame (ORF) in DNA, and a fold is a protein’s three-dimensional structure that allows it to perform its function or functions. Protein rarity can be defined as the proportion or prevalence of functional sequences, Pfs, in a region of sequence space, which equals the number of amino acid sequences that fold into the correct structure to perform a specific function divided by the total number of sequences within that region. Global rarity corresponds to the region encompassing all of sequence space. Rarity calculations constrain theories on the origin of natural proteins and strategies for engineering new proteins [1,2]. For instance, they yield estimates on the required biasing in sequence space for continuous paths of functional sequences to connect distinct proteins [3]. In addition, identifying the underlying constraints for protein function and their relationship to rarity assists in developing antibiotics [4] and enables better predictions of why genetic variants cause disease [5]. One class of experiments addressing protein rarity uses a forward approach where random sequences are selected for some predefined function, such as the ability to bind to ATP [6–10]. Such experiments frequently report that functional sequences are relatively common. However, the identified amino acid chains in these experiments only perform very simple activities. They lack the suite of properties often associated with natural proteins, such as the precise positioning of side chains to perform targeted molecular alterations and cooperative conformational changes that allow for complex catalytic and mechanical functions [11]. Other experiments use a reverse approach, where wildtype proteins are tested for how much randomization they can withstand and remain viable [12–15]. These studies consistently conclude that functional sequences corresponding to natural proteins are extremely rare. Yet experimental approaches are, by necessity, limited by the amount of sequence space investigators can sample, which is a minuscule portion. Sequences are mostly sampled in the region of sequence space close to a wildtype protein sequence, so estimates do not include substantive sampling of sequences with a larger number of amino acid alterations. The number of alterations, n, is known as the Hamming distance from the wildtype. Since sequences close to wildtype sequences (i.e., small n) are more tolerant to amino acid changes, researchers risk overestimating functional prevalence [1,16]. In addition, the extent to which results can be applied more generally to other proteins is uncertain. A more reliable approach for estimating rarity focuses on changes in protein stability and functional efficiency caused by accumulating mutations. This study has three primary aims: (1) to develop a generalizable framework—PRISM (Protein Rarity Inference from Stability and Mutational data)—for estimating protein rarity based on mutational effects on function and thermodynamic stability; (2) to apply PRISM to a diverse set of well-characterized proteins representing a range of structural and functional types; and (3) to evaluate the framework’s performance by comparing its rarity estimates with those derived from previous empirical and computational studies. Protein stability studies Protein stability has been traditionally defined as the free energy difference between the unfolded and native state: ΔGU−N. For instance, β-lactamase has a stability of approximately 11 kcal/mol [17]. Sorokina et al. (2022), in contrast, define protein stability as the depth of a local free energy minimum [18]. The preferred definition does not affect the analysis presented here. An unfolded chain “funnels” down the protein’s energy landscape (Fig 1a) toward the energy minimum corresponding to the native conformation, whose depth is ΔGU−N. Energy landscapes for different protein categories. (a) A protein’s energy landscape illustrating the unfolded, native, intermediate, and alternative states. The native state represents the free energy minimum for proteins under standard conditions. Protein folding corresponds to an unfolded amino acid chain (depicted at the top of the diagram) “funneling” down the energy landscape into a minimum energy basin via intramolecular contact formation. The basin contains numerous conformational substates. Local energy minima represent intermediate or alternative conformations, such as the amyloid state, which can occur if the correct environmental conditions are present. Illustration reproduced from Rashkatov and Teplow (2017) [19], licensed under CC BY 4.0. (b) Metamorphic protein transitioning between two distinct conformations. (c) Protein with a single native state corresponding to a global energy minimum. (d) Metamorphic protein with two conformations corresponding to separate energy minima. (e) Intrinsically disordered protein lacking a well-defined structure. Subfigures (b–e) adapted from Dishman and Volkman (2022) [20], licensed under CC BY 4.0. Zeldovich et al. (2007) reported that most proteins have a stability of 15 kcal/mol or less, with the highest recorded stabilities around 20 kcal/mol [21]. The investigators derived this range using data obtained from the ProTherm database, which contains free-energy changes (ΔΔG) resulting from mutations in proteins from diverse species. The database also includes ΔGU−N for several thousand proteins. The investigators fit the ΔΔG data to mutation-diffusion equations to derive the distribution of protein stabilities. They also directly constructed the protein stability distribution from the ΔGU−N recorded in the database. The derived distribution matches the distribution from the empirical data, demonstrating the accuracy of the stability range they reported. A key result from multiple studies is that the extent to which a mutation lowers a protein’s stability is very closely associated with the extent to which it degrades performance [22–24]. When the stability drops sufficiently, activity ceases. The average drop in stability due to a mutation (ΔΔG) is approximately 1 kcal/mol [25]. A second key result is that accumulating mutations often exhibit epistasis [1,26,27], which can be categorized into general and specific [28]. General epistasis refers to mutations that alter the physical properties of proteins (e.g., affinity for ligands, stability) in an additive manner but impact the performance non-additively due to the nonlinear relationship between the physical properties and their biological effects. Specific epistasis refers to mutations that physically interact such that their impact on physical properties is nonadditive. Positive specific epistasis can occur if one mutation undoes the negative impact of another, but negative specific epistasis is far more prevalent [28]. The most important implication of negative specific epistasis for PRISM methods is that fewer mutations are tolerated as mutations accumulate, so the local Pfs decreases rapidly with n. As mutations accumulate, they increase the probability that the next mutation will interact epistatically with an existing mutation, thus exacerbating the drop in stability. The combined effect of general and specific epistasis is that a drop in stability does not initially decrease performance significantly, but after a threshold is exceeded, performance quickly degrades with accumulating mutations [1]. As a result, nearly all functional sequences reside within a target region in sequence space bounded by a specific Hamming distance from the wildtype, nb. Methodology for estimating rarity PRISM incorporates a spectrum of novel methods for calculating protein rarity from the available data on the loss of stability and function caused by accumulating mutations. The schema maps to a process flowchart that uses a decision tree to determine the specific method. The choice of method is partially determined by the protein’s functional specificity, which represents the precision required in the location and orientation of a protein’s amino acids to perform a biological function at a level that benefits the organism. The available empirical data also determines the selected method and the values of the corresponding parameters. Since most of the methods are based on the physics of protein stability, they generate more reliable estimates that are not limited by sampling constraints. The first branch in the flowchart separates peptides, polypeptides, and simple proteins that perform low-specificity functions from proteins that perform high-specificity functions. Examples of low-specificity functions include simple binding, breaking weak chemical bonds, and catalyzing reactions that simple molecules can catalyze. For low-specificity proteins, Pfs can often be directly measured. High-specificity functions include breaking strong bonds, multistep reactions, and driving processes that require the protein to perform multiple highly coordinated conformational changes or precise interactions with other proteins. For high-specificity proteins, Pfs cannot be measured directly. The second branch separates high-specificity proteins based on whether P(n) can be defined—the probability that a protein is functional with n amino acid changes; if P(3) = 0.1, 10% of proteins with 3 altered amino acids from the wildtype are functional. The third branch separates proteins with known P(n) based on whether they display prevalent negative epistasis (aka epistatic proteins), and the fourth branch separates high-specificity proteins with unknown P(n) based on whether the percentage of tolerated mutations, Ptol, beyond a stability cutoff is known. Rarity is calculated for each category of proteins using the corresponding method specific to the demarcation criteria. The process flowchart is illustrated in Fig 2. PRISM Flowchart for estimating protein rarity. The flowchart illustrates the decision tree used to determine methods for calculating rarity. The methods include (1) using a random library of amino acid sequences to directly estimate the percentage of functional sequences, Pfs (yellow); (2) using the proportion of functional sequences with n altered amino acids, P(n), to (2a) identify a target region and calculate the upper bound to the proportion of functional sequences in the target, Pubt, & the probability of a random mutation residing in the target region, Pt, or (2b) calculate Pubt & the probability an undirected search could discover the target, Pdt, (green); (3) using the percentage of tolerated mutations, Ptol, to calculate the upper bound to the proportion of functional sequences, Pub; and (4) using the change in protein stability due to mutations (ΔΔG) data to calculate Pub (purple). In the last method, the percentage of non-destabilizing mutations, Pnd, is used as a proxy for Ptol. Non-destabilizing mutations are categorized as those that decrease ΔGU−N less than a threshold (ΔΔG